Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2096-2108

  Long, Xinghua ^a   Fan, Meiyun ^b   Bigsby, Robert M ^c,d   Nephew, Kenneth P ^a,c,d,e  

^a Indiana University School of Medicine   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; APIGENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; TAMOXIFEN; DRUG DERIVATIVE; ESR1 PROTEIN, HUMAN; ESTRADIOL; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTOR COACTIVATOR 3; PROTEIN KINASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE DERIVATIVE; TRANSACTIVATOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL MOTILITY; CELL STIMULATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HORMONE INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; TRANSCRIPTION INITIATION; BREAST TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN BINDING; PROTEIN TRANSPORT; REPORTER GENE; TUMOR CELL LINE;

APIGENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENES, REPORTER; HISTONE ACETYLTRANSFERASES; HUMANS; HYDROXYTESTOSTERONES; PROTEIN BINDING; PROTEIN KINASES; PROTEIN TRANSPORT; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 51049098742     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2350     Document Type: Article

References (53)

1. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor a after PKA activation in breast cancer. Cancer Cell 2004;5:597-605.
2. Hyder SM, Chiappetta C, Murthy L, Stancel GM. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res 1997;57:2547-9.
3. Nicholson RI, Johnston SR. Endocrine therapy - current benefits and limitations. Breast Cancer Res Treat 2005;93 Suppl 1:S3-10.
4. Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res 2001;7:4402-10s; discussion 11-2s.
5. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005;19:833-42.
6. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
7. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005;12:599-614.
8. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
9. Fan M, Yan PS, Hartman-Frey C, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006;66:11954 -66.
10. Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther 2006;5:843-52.
11. Birt DF, Walker B, Tibbels MG, Bresnick E. Anti-mutagenesis and antipromotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 1986;7:959-63.
12. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997;28:236-47.
13. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001;90:157-77.
14. Wei H, Tye L, Bresnick E, Birt DF. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res 1990;50:499-502.
15. 2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 2001;21:413-20.
16. 2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 2000;28:102-10.
17. Mai Z, Blackburn GL, Zhou JR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog 2007;46:534-42.
18. Way TD, Kao MC, Lin JK. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 2004;279:4479-89.
19. Collins-Burow BM, Burow ME, Duong BN, McLachlan JA. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer 2000;38:229-44.
20. Huang YT, Kuo ML, Liu JY, Huang SY, Lin JK. Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin. Eur J Cancer 1996;32A:146-51.
21. Seo HS, DeNardo DG, Jacquot Y, et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER α. Breast Cancer Res Treat 2006;99:121-34.
22. Long X, Gize EA, Nephew K, Bigsby RM. Evidence for estrogenic contamination of the MAPK inhibitor PD98059. Endocrinology 2001;142:5390-3.
23. Stenoien DL, Patel K, Mancini MG, et al. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 2001;3:15-23.
24. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
25. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
26. Fan M, Long X, Bailey JA, et al. The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 2002;16:315-30.
27. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 2006;281:9607-15.
28. Hirano T, Oka K, Akiba M. Antiproliferative effects of synthetic and naturally occurring flavonoids on tumor cells of the human breast carcinoma cell line, ZR-75-1. Res Commun Chem Pathol Pharmacol 1989;64:69-78.
29. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise [review]. Int J Oncol 2007;30:233-45.
30. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280:5636-45.
31. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 1999;13:1522-34.
32. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
33. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 2007;6:1102-14.
34. Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Minirev Med Chem 2006;6:401-7.
35. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003;89:185-91.
36. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005;19:342-53.
37. Zwart W, Griekspoor A, Berno V, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERα towards coactivator SRC-1. EMBO J 2007;26:3534-44.
38. Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 2004;39:114-26.
39. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor α-induced nuclear factor (NF)-κB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-κB-responsive genes. Clin Cancer Res 2004;10:3169-78.
40. Mak P, Leung YK, Tang WY, Harwood C, Ho SM. Apigenin suppresses cancer cell growth through ERβ. Neoplasia 2006;8:896-904.
41. Osada M, Imaoka S, Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1α protein. FEBS Lett 2004;575:59-63.
42. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84.
43. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003;9:4961-71.
44. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74.
45. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006;20:3120-32.
46. Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, Brown M. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res 2006;66:11381-8.
47. Wu RC, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 2007;129:1125-40.
48. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994;269:4458-66.
49. Felekkis KN, Narsimhan RP, Near R, et al. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res 2005;3:32-41.
50. Shin I, Arteaga CL. Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 cells. IUBMB Life 2006;58:664-9.
51. Balasubramanian S, Zhu L, Eckert RL. Apigenin inhibition of involucrin gene expression is associated with a specific reduction in phosphorylation of protein kinase Cδ Tyr311. J Biol Chem 2006;281:36162-72.
52. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995;92:7686-9.
53. Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res 2007;9:R80.